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Cancer cells induce a set of adaptive response pathways to survive in the face of stressors due to inadequate vascularization 1 . One such adaptive pathway is the unfolded protein (UPR) or endoplasmic reticulum (ER) stress response mediated in part by the ER-localized transmembrane sensor IRE1 (ref.
2) and its substrate XBP1 (ref. 3) . Previous studies report UPR activation in various human tumours [4] [5] [6] , but the role of XBP1 in cancer progression in mammary epithelial cells is largely unknown. Triple-negative breast cancer (TNBC)-a form of breast cancer in which tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also called ERBB2 or NEU)-is a highly aggressive malignancy with limited treatment options 7, 8 . Here we report that XBP1 is activated in TNBC and has a pivotal role in the tumorigenicity and progression of this human breast cancer subtype. In breast cancer cell line models, depletion of XBP1 inhibited tumour growth and tumour relapse and reduced the CD44 high CD24 low population. Hypoxia-inducing factor 1a (HIF1a) is known to be hyperactivated in TNBCs 9, 10 . Genome-wide mapping of the XBP1 transcriptional regulatory network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex with HIF1a that regulates the expression of HIF1a targets via the recruitment of RNA polymerase II. Analysis of independent cohorts of patients with TNBC revealed a specific XBP1 gene expression signature that was highly correlated with HIF1a and hypoxia-driven signatures and that strongly associated with poor prognosis. Our findings reveal a key function for the XBP1 branch of the UPR in TNBC and indicate that targeting this pathway may offer alternative treatment strategies for this aggressive subtype of breast cancer.
We determined UPR activation status in several breast cancer cell lines. XBP1 expression was readily detected in both luminal and basallike breast cancer cell lines, but the level of its spliced form was higher in the latter which consist primarily of TNBC cells; XBP1 activation was also higher in primary TNBC patient samples (Fig. 1a, b ). PERK but not ATF6 was also activated (Extended Data Fig. 1a ), and transmission electron microscopy revealed more abundant and dilated ER in multiple TNBC cell lines (Extended Data Fig. 1b) . These data reveal a state of basal ER stress in TNBC cells.
XBP1 silencing impaired soft agar colony-forming ability and invasiveness (Extended Data Fig. 1c ) of multiple TNBC cell lines, indicating that XBP1 regulates TNBC anchorage-independent growth and invasiveness. We next used an orthotopic xenograft mouse model with inducible expression of two XBP1 short hairpin RNAs (shRNAs) in MDA-MB-231 cells. Tumour growth and metastasis to lung were significantly inhibited by XBP1 shRNAs (Fig. 1c-e and Extended Data Fig. 1d-g) . This was not due to altered apoptosis (caspase 3), cell proliferation (Ki67) or hyperactivation of IRE1 and other UPR branches ( Fig. 1e and Extended Data Fig. 1h , i). Instead, XBP1 depletion impaired angiogenesis as demonstrated by the presence of fewer intratumoral blood vessels (CD31 staining) ( Fig. 1e ). Subcutaneous xenograft experiments using two other TNBC cell lines confirmed our findings (Extended Data Fig. 1j, k) . Notably, XBP1 silencing in a patient-derived TNBC xenograft model (BCM-2147) significantly decreased tumour incidence ( Fig. 1f and Extended Data Fig. 1l, m) .
TNBC patients have the highest rate of relapse within 1-3 years despite adjuvant chemotherapy 7, 8 . To examine XBP1's effect on tumour relapse after chemotherapeutic treatment, we treated MDA-MB-231 xenograftbearing mice with doxorubicin and XBP1 shRNA. Notably, combination treatment not only blocked tumour growth but also inhibited or delayed tumour relapse ( Fig. 2a ).
Tumour cells expressing CD44 high CD24 low have been shown to mediate tumour relapse in some instances [11] [12] [13] . To test whether XBP1 targeted the CD44 high CD24 low population, we examined the mammosphere-forming ability of cells derived from treated tumours (day 20). Mammosphere formation was increased in doxorubicin-treated tumour cells, whereas tumours treated with doxorubicin plus XBP1 shRNA displayed substantially reduced mammosphere formation (Fig. 2b) , a finding confirmed using another chemotherapeutic agent, paclitaxel (Extended Data Fig. 2a, b ). Hypoxia activates the UPR, and XBP1 knockdown also markedly reduced mammosphere formation in hypoxic conditions (Extended Data Fig. 2b ). Furthermore, CD44 expression was reduced in XBP1depleted tumours (Extended Data Fig. 2c ).
To interrogate XBP1's effect on CD44 high CD24 low cell function further, we used mammary epithelial cells (MCF10A) carrying an inducible Src oncogene (ER-Src), where v-Src is fused with the oestrogen receptor ligand-binding domain 14 . Tamoxifen treatment results in neoplastic transformation and gain of a CD44 high CD24 low population that has been previously associated with tumour-initiating properties 15 . In transformed MCF10A-ER-Src cells, XBP1 splicing was increased in the CD44 high CD24 low population ( Fig. 2c ), whereas XBP1 silencing reduced the CD 44 high CD24 low fraction (Extended Data Fig. 2d , e) and markedly suppressed mammosphere formation (Extended Data Fig. 2f ), phenotypes not attributable to a direct effect of XBP1 on cell viability (Extended Data Fig. 2g, h ). Furthermore, limiting dilution experiments demonstrated loss of tumour-seeding ability in XBP1-depleted cells ( Fig. 2d ). CD44 high CD24 low cells sorted from TNBC patient samples confirmed increased XBP1 splicing and other UPR markers, and XBP1 silencing impaired mammosphere-forming ability ( Fig. 2e , f and Extended Data Fig. 3a ). Conversely, overexpression of spliced XBP1 (XBP1s) in CD44 low CD24 high cells resulted in gain of mammosphere-forming ability and increased resistance to doxorubicin treatment (Extended Data Fig. 3b , c). Notably, patient-derived CD44 low CD24 high cells overexpressing XBP1s, but not control parental cells, initiated tumour formation in immunodeficient mice (Extended Data Fig. 3d , e). These data establish a critical role of XBP1 in CD44 high CD24 low cells within TNBC.
Chromatin immunoprecipitation coupled with ultra-high-throughput DNA sequencing (ChIP-seq) and motif analysis of XBP1 in MDA-MB-231 cells revealed statistically significant enrichment of both the HIF1a and XBP1 motifs ( Fig. 3a and Extended Data Fig. 4a ), indicating frequent co-localization of HIF1a and XBP1 to the same regulatory elements. HIF1a is hyperactivated in TNBCs, required for the maintenance of CD44 high CD24 low cells 9, 10, 16, 17 , and is regulated in response to microenvironmental oxygen levels. XBP1 ChIP-seq was therefore also carried out in MDA-MB-231 and Hs578T cells cultured under hypoxia and glucose deprivation conditions for 24 h. Exposure to these stressors increased XBP1 splicing, resulting in a corresponding increase in signal intensity (Extended Data Fig. 4b-f ) and further enrichment of HIF1a motifs in TNBC ( Fig. 3a ), but interestingly not in luminal breast cancer cells (Extended Data Fig. 4g ).
HIF1a motif enrichment in the XBP1 ChIP-seq data set indicated that XBP1 and HIF1a might interact within the same transcriptional complex. . c, RT-PCR analysis of XBP1 splicing in tamoxifen-treated CD44 low CD24 high and CD44 high CD24 low cells. d, The indicated number of tamoxifen-treated MCF10A-ER-Src cells infected with control shRNA or XBP1 shRNA were injected into NOD/SCID/Il2rc 2/2 mice and the tumour incidence reported at 12 weeks after transplantation. e, RT-PCR analysis of XBP1 splicing in CD44 low CD24 high and CD44 high CD24 low cells purified from a TNBC patient. f, Number of mammospheres per 1,000 cells generated from primary tissue samples from five patients with TNBC (br ca 1-5) that were untreated or infected with lentiviruses encoding control shRNA or XBP1 shRNA. Data are shown as mean 6 s.d. of technical triplicates.
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Co-immunoprecipitation experiments revealed a physical interaction of HIF1a, but not HIF2a, with XBP1 in 293T cells co-expressing HIF1 and XBP1s cultured under hypoxic conditions; an interaction was also observed with endogenous proteins in two TNBC cell lines: MDA-MB-231 and Hs578T ( Fig. 3b and Extended Data Fig. 4h -j). Subcellular fractionation revealed that this interaction occurs in the nucleus, and that unspliced XBP1u protein was not detectable (Extended Data Fig. 4k , l). Glutathione S-transferase (GST) pull-down experiments showed that HIF1a interacts with the XBP1s amino-terminus b-zip domain (Extended Data Fig. 4m , n).
We next established that XBP1 and HIF1a co-occupied several wellknown HIF1a targets using ChIP-qPCR (Extended Data Fig. 5a -c). ChIPre-ChIP assays using anti-XBP1s followed by anti-HIF1a antibodies confirmed that XBP1s and HIF1a simultaneously co-occupy these common targets (Extended Data Fig. 5d ). DNA pull-down assays with a HIF1a (ref. 18 ) specific probe precipitated XBP1s in MDA-MB-231 nuclear extracts under hypoxia, indicating their presence in the same complex (Extended Data Fig. 5e , f). XBP1 depletion by two independent shRNA constructs markedly reduced hypoxia response element (HRE) luciferase activity under hypoxia ( Fig. 3c ). Conversely, XBP1s expression dose-dependently transactivated the HRE reporter (Extended Data Fig. 5g , h), confirming that XBP1 augments HIF1a activity.
When we profiled the differential transcriptome induced by XBP1 silencing in MDA-MB-231 cells, gene-set enrichment analysis identified significant enrichment of HIF1a-mediated hypoxia response pathway genes ( Fig. 3d and Extended Data Fig. 6a ). XBP1 depletion downregulated 
LETTER RESEARCH
HIF1a targets VEGFA, PDK1, GLUT1 (also called SLC2A1) and DDIT4 expression in both normoxic and hypoxic conditions (Extended Data Fig. 6b ), and these results were validated in breast cancer xenografts ( Fig. 3e ) and Hs578T cells (Extended Data Fig. 6c ). However, XBP1 depletion in luminal tumours did not affect these targets (Extended Data Fig. 6d ).
To explore the consequences of this cooperation further, we examined how XBP1 or HIF1a loss affected the transcription of common target genes. We found that high XBP1 occupancy at its binding sites was associated with increased occurrence of the HIF1a motif across the genome in TNBC (Fig. 3f ). Whereas XBP1 depletion had no immediate effect on HIF1a expression, it substantially attenuated concurrent HIF1a and RNA polymerase II occupancy (Extended Data Fig. 6e-g and Fig. 3g ). Similarly, XBP1 and RNA polymerase II occupancy at cobound sites was likewise reduced in the absence of HIF1a under hypoxic conditions ( Fig. 3h and Extended Data Fig. 6h-l) . These results indicate that the assembly of the XBP1-HIF1a complex on target promoters is crucial for their transcription, via the recruitment of RNA polymerase II.
To establish whether HIF1a contributes to the function of XBP1 in TNBC, we performed rescue experiments using a haemagglutinin (HA)tagged constitutively activated hydroxylation-mutant HIF1a construct (HA-HIF1a dPA: P402A/P564A). XBP1 splicing was not directly regulated by HIF1a (Extended Data Fig. 7a-c) . Enforced overexpression of HIF1a dPA in XBP1-depleted cells restored expression of HIF1a targets and rescued anchorage-independent growth, mammosphere-forming ability, angiogenesis and in vivo tumour growth ( Fig. 3i and Extended Data Fig. 7d-h) . Conversely, HIF1a silencing in XBP1s overexpressing cells markedly compromised their ability to sustain mammosphere formation (Extended Data Fig. 7i ). Hypoxia is a physiological UPR inducer in cancer 19 and XBP1s co-localizes with hypoxia marker CA9 in tumours 20 . Our experiments demonstrate that XBP1 functions to sustain the hypoxia response via regulating the HIF1a transcriptional program (Extended Data Fig. 8 ), which ensures maximum HIF activity and adaptive responses to the cytotoxic microenvironment of solid tumours.
Integrated analysis of XBP1 ChIP-seq data and gene expression profiles identified 96 genes directly bound and upregulated by XBP1. This gene set was defined as the XBP1 signature ( Fig. 4a and Supplementary  Table 1 ). Its expression was highly correlated with hypoxia-driven signatures in TNBC (Pearson's correlation coefficient 5 0.61; P 5 2.283 10 260 ), but not in ER 1 breast cancer patients (coefficient 5 0.03; P 5 0.64) (Extended Data Fig. 9a, b ). Survival analysis using an aggregate breast cancer data set for 193 TNBC patient samples 21 demonstrated that tumours with an elevated XBP1 signature displayed shorter relapse-free survival (log-rank test, P 5 0.00677) ( Fig. 4b ). Cox regression analysis showed that association of the signature with relapse-free survival remained significant after controlling for tumour size, grade and chemotherapy treatment (P 5 0.00453, Supplementary Table 2 ). These findings were validated in a separate cohort of 190 TNBC patients ( Fig. 4c ). Importantly, the XBP1 signature did not correlate with clinical outcome of ER 1 breast cancer patients (P 5 0.553) (Extended Data Fig. 9c ), indicating its specific prognostic value for TNBC. Expression of the XBP1-regulated HIF1a program was also associated with decreased relapse-free survival only in TNBC (P 5 0.00911) ( Fig. 4d and Extended Data Fig. 9d ). Although XBP1 silencing also affects luminal breast cancer growth, it does so via a mechanism not involving HIF1a (Extended Data Figs 4g, 6d and 10).
In conclusion, we have uncovered a key function of XBP1 in the tumorigenicity, progression and recurrence of TNBC, and have identified XBP1's control of the HIF1a transcriptional program as the major mechanism. XBP1 pathway activation correlates with poor patient survival in TNBC patients, indicating that UPR inhibitors in combination with standard chemotherapy may improve the effectiveness of antitumour therapies.
METHODS SUMMARY
Orthotopic tumour growth assays. Female NOD/SCID/Il2rc 2/2 or nude mice (Taconic) were injected orthotopically with 1.5 3 10 6 viable tumour cells re-suspended in 40 ml Matrigel (BD Biosciences) into mammary glands and fed chow containing 6 g doxycycline per kg (Bioserv). For bioluminescent detection, mice were given a single intraperitoneal injection of luciferin, ketamine and xylazine and imaged with an IVIS imaging camera (Xenogen). Imaging intensity was normalized to the luminescence signal of individual mice before doxycycline chow treatment. The average luminescence ratio of treatment groups (lacZ or XBP1 shRNA) was plotted over the course of doxycycline chow treatment and results presented as mean 6 s.d. Mammosphere formation assay. Mammospheres were generated from cells in suspension (1,000 cells ml 21 ) in serum-free DMEM/F12 media, supplemented with B27 (1:50, Invitrogen), 0.4% BSA, 20 ng ml 21 EGF and 4 mg ml 21 insulin. After 6 days mammospheres were typically .75 mm in size with ,97% CD44 high CD24 low . For serial passaging, 6-day-old mammospheres were collected, dissociated to single cells with trypsin and re-grown in suspension for 6 days. 
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Cell culture and treatments. The non-transformed breast cell line MCF10A contains an integrated fusion of the v-Src oncoprotein with the ligand-binding domain of the oestrogen receptor (ER-Src). These cells were grown in DMEM/F12 medium supplemented with 5% donor horse serum (Invitrogen), 20 ng ml 21 epidermal growth factor (EGF) (R&D systems), 10 mg ml 21 insulin (Sigma), 100 mg ml 21 hydrocortisone (Sigma), 100 ng ml 21 cholera toxin (Sigma), 50 units ml 21 penicillin/streptomycin (Gibco), with the addition of puromycin (Sigma). Src induction and cellular transformation was achieved by treatment with 1 mM 4-OH tamoxifen, typically for 36 h, as described previously 14 .
All breast cancer cells were from ATCC cultured according to ref. 24. After retroviral or lentiviral infection, cells were maintained in the presence of puromycin (2 mg ml 21 ) (Sigma). For all hypoxia experiments, cells were maintained in an anaerobic chamber (Coy laboratory) with 0.1% O 2 . For glucose deprivation experiments, cells were maintained in DMEM without glucose medium (Gibco) with 10% FBS (Gibco) and 50 units ml 21 of penicillin/streptomycin. ChIP and ChIP-seq. ChIP was performed with XBP1 antibody (Biolegend, 619502); HIF1a antibody (Abcam, ab2185), RNA polymerase II antibody (Millipore, 05-623) or GST antibody (Santa Cruz, sc-33613) as described 25 . See list of primers used in Fig. 3 (Supplementary Table 3 ). ChIP-seq libraries were prepared using the ChIP-Seq DNA Sample Prep kit (Illumina). XBP1 ChIP-seq peaks were first identified using MACS package with a P value cutoff of 1 3 10 27 on individual replicate. Correlations of the ChIP-seq signal in the union peak regions between two biological replicates are: MDA-MB-231_untreated, 0.97 (P , 2.2 3 10 216 ); MDA-MB-231_HG, 0.96 (P , 2.2 3 10 216 ); Hs578T_HG, 0.98 (P , 2.2 3 10 216 ); T47D_HG, 0.99 (P , 2.2 3 10 216 ). The correlations were calculated by cor.test() function in R (http://www.r-project.org/). The highly confident common peaks between replicates were further identified using an irreproducible discovery rate (IDR) cutoff of 20%. IDR is a statistical measure that assesses the consistency of the rank orders of the common ChIP-seq peaks between two replicates. The methodology and details of the implementation of IDR can be found in ref. 26 . Tumour initiation assay using patient-derived tumours. Tumour graft line BCM-2147 was derived by transplantation of a fresh patient breast tumour biopsy (ER 2 PR 2 HER2 2 ) into the cleared mammary gland fat pad of immune-compromised SCID/Beige mice and retained the patient biomarker status and morphology across multiple transplant generations in mice. To overcome the challenge of limited cell viability by dissociation of solid tumours, 10 mg tumour pieces containing 1.3 3 10 5 cells were transplanted with basal membrane extract (Trevigen). The cell number was calculated as average cell yield 1.3 3 10 7 cells per gram 3 0.01 g 5 1.3 3 10 5 cells. For sustained siRNA release in the first 2 weeks after transplantation, porous silicon particles loaded with siRNA (scrambled control or XBP1 siRNA) packaged in nanoliposomes were injected into the tumour tissue with basal membrane extract at the time of transplantation. Scrambled sequence, 59-CGAAGUGUGUGUGUG UGGCdTdT-39; XBP1 siRNA sequence 59-CACCCUGAAUUCAUUGUCUdTd T-39. Two weeks after transplantation, nanoliposomes containing siRNA (15 mg per mouse) were injected intravenously twice weekly for 8 weeks. Mice were monitored thrice weekly for tumour development, and tumours were calipered and recorded using LABCAT Tumour Analysis and Tracking System v6.4 (Innovative Programming Associates, Inc.). Tumour incidence is reported at 10 weeks after transplantation. The human patient samples were procured and used according to approved IRB protocols for research in human subjects. Invasion assay. We performed invasion assays according to ref. 14. Invasion of the matrigel was conducted by using standardized conditions with BD BioCoat growthfactor-reduced matrigel invasion chambers (PharMingen). Assays were conducted according to manufacturer's protocol, by using 5% horse serum (Gibco) and 20 ng ml 21 EGF (R&D Systems) as chemo-attractants. Colony formation assay. 1 3 10 5 breast cancer cells were mixed 4:1 (v/v) with 2.0% agarose in growth medium for a final concentration of 0.4% agarose. The cell mixture was plated on top of a solidified layer of 0.8% agarose in growth medium. Cells were fed every 6-7 days with growth medium containing 0.4% agarose. The number of colonies was counted after 20 days. The experiment was repeated three times and the statistical significance was calculated using a Student's t-test. Subcutaneous xenograft experiments. MCF10A ER-Src tamoxifen-treated (36 h) cells or MDA-MB-436 or HBL-100 breast cancer cells were injected subcutaneously in the right flank of athymic nude mice (Charles River Laboratories). Tumour growth was monitored every 5 days and tumour volumes were calculated by the equation V(mm 3 ) 5 ab 2 /2, where a is the largest diameter and b is the perpendicular diameter. When the tumours reached a size of ,100 mm 3 (15 days) mice were randomly distributed into 3 groups (5 mice per group). The first group was used as control (non-treated), the second group was intratumorally treated with shCtrl and the third group was intratumorally treated with shXBP1. For each injection 10 mg of shRNA was mixed with 2 ml of vivo-jetPEI (polyethylenimine) reagent (catalogue no. 201-50G, PolyPlus Transfection SA) in a final volume of 100 ml. These treatments were repeated every 5 days for 4 cycles (days 15, 20, 25 and 30). In addition, in vivo dilution xenotransplantation assays were performed in NOD/SCID/Il2rc 2/2 mice. Mice were evaluated on a weekly basis for tumour formation. All mice were maintained in accordance with Dana-Farber Cancer Institute Animal Care and Use Committee procedures and guidelines. Purification of CD44 high CD24 low and CD44 low CD24 high cells from patients with TNBC. Five human invasive triple-negative ductal carcinoma tissues (stage III) were used in our experiments 15 . Immunomagnetic purification of CD44 high CD24 low and CD44 low CD24 high cells was performed according to ref. 27. Briefly, the breast tissues were minced into small pieces (1 mm) using a sterile razor blade. The tissues were digested with 2 mg ml 21 collagenase I (C0130, Sigma) and 2 mg ml 21 hyalurinidase (H3506, Sigma) in 37 uC for 3 h. Cells were filtered, washed with PBS and followed by Percoll gradient centrifugation. The first purification step was to remove the immune cells by immunomagnetic purification using an equal mix of CD45 (leukocytes), CD15 (granulocytes), CD14 (monocytes) and CD19 (B cells) Dynabeads (Invitrogen). The second purification step was to isolate fibroblasts from the cell population by using CD10 beads for magnetic purification. The third step was to isolate the endothelial cells by using an 'endothelial cocktail' of beads (CD31 BD Pharmingen catalogue no. 555444, CD146 P1H12 MCAM BD Pharmingen catalogue no. 550314, CD105 Abcam catalogue no. Ab2529, cadherin 5 Immunotech catalogue no. 1597, and CD34 BD Pharmingen catalogue no. 555820). In the final step the CD44 high cells were purified from the remaining cell population using CD44 beads. These cells were sorted for CD44 high CD24 low cells, CD24 high cells were also purified using CD24 beads. These cells were sorted for CD44 low CD24 high cells. These cell populations were sorted again with CD44 antibody (FITCconjugated) (555478, BD Biosciences) and CD24 antibody (PE-conjugated) (555428, BD Biosciences) to increase their purity (.99.2% in all cases). Gene expression microarray analysis. MDA-MB-231 cells infected with control shRNA or XBP1 shRNA lentiviruses grown in glucose-free medium were treated in 0.1% O 2 in a hypoxia chamber for 24 h. Total RNA was extracted by using RNeasy mini kit with on column DNase digestion (Qiagen). Biotin-labelled cRNA was prepared from 1 mg of total RNA, fragmented, and hybridized to Affymetrix human U133 plus 2.0 expression array. All gene expression microarray data were normalized and summarized using RMA. The differentially expressed genes were identified using Limma (q # 10%). Motif analysis. Flanking sequences around the summits (6300 bp) of the top 1,000 XBP1 binding sites were extracted and the repetitive regions in these flanking sequences were masked. The consensus sequence motifs were derived using Seqpos. XBP1 signature generation. The XBP1 signature was generated by integrative analysis of ChIP-seq and differential expression data using the method as previously described 28 . Briefly, we first calculated the regulatory potential for a given gene, S g , as the sum of the nearby binding sites weighted by the distance from each site to the transcription start site (TSS) of the gene S g~X k i~1 e {(0:5z4Di) , where k is the number of binding sites within 100 kb of gene g and Di is the distance between site i and the TSS of gene g normalized to 100 kb (for example, 0.5 for a 50-kb distance). We then applied the Breitling's rank product method to combine regulatory potentials with differential expression t-values to rank all genes based on the probability that they were XBP1 targets. Only genes with at least one binding site within 100 kb from its TSS and a differential expression t-value above the 75th percentile were considered. The FDR of XBP1 target prediction was estimated by permutation. At a FDR cutoff of 20% and differential expression fold-change cutoff of 1.5, we obtained 96 upregulated genes (HUGO gene symbol) as direct targets of XBP1. Survival analysis. We performed survival analysis using an aggregated compendium of gene expression profiles of 383 TNBC samples from 21 breast cancer data sets 21 . Of the 96 XBP1 signature genes, 70 genes had corresponding probes in this data set. To avoid potential confounding factors such as heterogeneity among the samples, we randomly split all 383 TNBC samples into two data sets with similar size (193 and 190 cases) and evaluated the correlation of the XBP1 gene signature with relapse-free survival using these two data sets, respectively. We separated patients into two subgroups: one with higher and the other with lower expression of the XBP1 signature. The subgroup classification was performed as described previously 29 . Patients were considered to have a higher XBP1 signature if they had average expression values of all the genes in the XBP1 signature above the 58th percentile 29 . Kaplan-Meier survival analysis was performed and log-rank test was used to assess the statistical significance of survival difference between these two groups. We also performed multivariate Cox regression analysis to evaluate the significance of the association between XBP1 signature and relapse-free survival in the presence of other clinical variables including tumour stage, tumour grade and the treatment with chemotherapy. A similar analysis was performed for the HIF pathway signature (VEGFA, PDK1, DDIT4, SLC2A1, KDM3A, NDRG1, PFKFB3, PIK3CA, RORB, CREBBP, PIK3CB, HK2 and EGLN1). Similar to the analysis for TNBC, the survival analysis was performed for ER 1 breast cancer using gene expression profiles and clinical annotations of 209 ER 1 breast cancer patients 30 . Virus production and infection. The Phoenix packaging cell line was used for the generation of ecotropic retroviruses and the 293T packaging cell line was used for lentiviral amplification. In brief, viruses were collected 48 and 72 h after transfection, filtered, and used for infecting cells in the presence of 8 mg ml 21 polybrene before drug selection with puromycin (2 mg ml 21 ). shRNA constructs were generated by The Broad Institute. Targeting of GFP mRNA with shRNA served as a control. Optimal targeting sequences identified for human XBP1 were 59-GACCC AGTCATGTTCTTCAAA-39, and 59-GAACAGCAAGTGGTAGATTTA-39, respectively. Knockdown efficiency was assessed by real-time PCR for XBP1. Luciferase assay. For Extended Data Fig. 5g , MDA-MB-231 cells were co-transfected with 33HRE luciferase (33HRE-Luc) plasmid and XBP1s overexpression construct or control vector by using Lipofectamine 2000 (Invitrogen). A Renilla luciferase plasmid (pRL-CMV from Promega) was co-transfected as an internal control. Cells were collected 36 h after transfection, and the luciferase activities of the cell lysates were measured by using the Dual-luciferase Reporter Assay System (Promega). For Fig. 3c , MDA-MB-231 cells were co-transfected with 33HRE-Luc and two inducible XBP1 shRNA constructs (in pLKO-Tet-On vector) or control shRNA construct by using Lipofectamine 2000 (Invitrogen). Cells were treated with doxycycline for 48 h and hypoxia for 24 h before the luciferase activities of the cell lysates were measured. Statistical analysis. The significance of differences between treatment groups was measured with a Student's t-test. P values of less than 0.05 were considered statistically significant. Co-immunoprecipitation. Transfected cells were lysed in cell lysis buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and 10% glycerol with protease inhibitor cocktail) for 1 h. M2 beads (Sigma) were incubated with the whole-cell extracts at 4 uC overnight. The beads were washed with cell lysis buffer four times. Finally, the beads were boiled in 23 sample buffer for 10 min. The eluents were analysed by western blot. Nuclear extracts were used to perform the endogenous co-immunoprecipitation. Briefly, 5 mg of nuclear extracts were incubated with 5 mg of anti-HIF1a antibody (Novus Biologicals, NB100-479) at 4 uC overnight. The protein complexes were precipitated by addition of protein A agarose beads (Roche) with incubation for 4 h at 4 uC. The beads were washed four times and boiled for 5 min in 23 sample buffer. Real-time PCR analysis. 1 mg of RNA sample was reverse-transcribed to form cDNA, which was subjected to SYBR-green-based real-time PCR analysis. Primers used for b-actin forward: 59-CCTGTACGCCAACACAGTGC-39 and reverse 59-ATACTCCTGCTTGCTGATCC-39; for VEGFA forward 59-CACACAGGATG GCTTGAAGA-39 and reverse 59-AGGGCAGAATCATCACGAAG-39; for PDK1 forward 59-GGAGGTCTCAACACGAGGTC-39 and reverse 59-GTTCATGTCA CGCTGGGTAA-39; for GLUT1 forward 59-TGGACCCATGTCTGGTTGTA-39 and reverse 59-ATGGAGCCCAGCAGCAA-39; for JMJD1A forward 59-TCAGG TGACTTTCGTTCAGC-39 and reverse 59-CACCGACGTTACCAAGAAGG-39; for DDIT4 forward 59-CATCAGGTTGGCACACAAGT-39 and reverse 59-CCT GGAGAGCTCGGACTG-39; for MCT4 forward 59-TACATGTAGACGTGGG TCGC-39 and reverse 59-CTGCAGTTCGAGGTGCTCAT-39; for XBP1 splicing forward 59-CCTGGTTGCTGAAGAGGAGG-39 and reverse 59-CCATGGGGAG ATGTTCTGGAG-39; for XBP1 total forward 59-AGGAGTTAAGACAGCGCT TGGGGATGGAT-39 and reverse 59-CTGAATCTGAAGAGTCAATACCGCCA GAAT-39. ChIP-re-ChIP. XBP1 antibody was crosslinked to protein G-Sepharose beads using dimethylpimelimidate to prevent the leaching of antibody during sodium dodecyl sulphate (SDS) elution. The beads were then incubated with chromatin extracts overnight. Subsequently, the beads were washed and eluted with 1% SDS elution buffer at 37 uC for 45 min. The eluate was diluted to a final SDS concentration of 0.1% and incubated with fresh antibody-bound beads for the second immunoprecipitation. For the final round of immunoprecipitation, washed beads were eluted with 1% SDS elution buffer at 68 uC for 30 min. Eluate was de-crosslinked in the presence of pronase and heated at 68 uC for 6 h, and DNA was purified by phenolchloroform extraction. Glutathione S-transferase pull-down assay. Various deletion fragments of XBP1s were cloned into pET42b (Novagen). The plasmids were transformed into BL21 Escherichia coli. The XBP1s proteins were expressed and purified with glutathione (GSH)-Sepharose beads (GE Healthcare). The purified proteins were bound to GSH beads and incubated with HIF1a-overexpressed cell lysates for 2 h in 4 uC. The beads were washed six times with cell lysis buffer. The eluents were analysed by western blot. DNA-binding assay. Nuclear protein (150 mg) was incubated for 1 h at 4 uC with a biotinylated probe containing wild-type or mutated HIF1a binding site plus streptavidin-dynabeads (Invitrogen) in binding buffer (100 mM NaCl, 10 mM Tris-HCl, pH 7.6, 0.1 mM EDTA, 1 mM dithiothreitol, 5% glycerol, 1 mg ml 21 of BSA and 20 mg ml 21 of poly(dI:dC), plus protease inhibitors). Streptavidin beads were washed in binding buffer, and bound proteins were analysed by immunoblot for XBP1s or HIF1a. Transmission electron microscopy. Cells were washed with serum-free media then fixed with a modified Karmovsky's fix of 2.5% glutaraldehyde, 4% paraformaldehyde and 0.02% picric acid in 0.1 M sodium caocdylate buffer at pH 7.2. After a secondary fixation in 1% osmium tetroxide, 1.5% potassium ferricyanide, samples were dehydrated through a graded ethanol series, and embedded in situ in an epon analogue resin. En face ultrathin sections were cut on a Leica Ultractu S Ultramicrotome (Leica). Sections were collected on copper grids and further contrasted with lead citrate and viewed on a JEM 1400 electron microscope (JEOL) operated at 100 kV. Digital images were captured on a Veleta 2K 3 2K CCD camera (Olympus-SIS). Caspase 3 ELISA assay. Quantification of cleaved caspase-3 activity was performed using the PathScan Cleaved Caspase-3 (Asp175) sandwich ELISA kit (no. 7190, Cell Signaling) according to the manufacturer's recommendations. Immunohistochemical staining. We fixed xenograft tumour tissues in 4% paraformaldehyde and performed immunohistochemistry on 5-mm-thick paraffin sections after heat-induced antigen retrieval. The following primary antibodies were used: CD31 (1:50, Abcam, ab28364), cleaved caspase 3 (1:200, Cell Signaling, 9664), CD44 (1:100, Novocastra), Ki67 (1:50, Dako, Clone MIB-1), and carbonic anhydrase IX (1:40, Novus Biologicals). Subsequently, we incubated the slides with biotinylated secondary antibody and ABC-HRP (both from Vector Lab). EnVision1 system (Dako) was used to amplify caspase 3 and carbonic anhydrase IX. Mouse on Mouse ImmPRESS Polymer kit (Vector Lab) was applied to increase CD44 signalto-noise ratio. For all slides, final detectable signal was visualized by DAB as the location of antigens. After counterstaining with haematoxylin, slides were mounted. Immunoblot analysis. Total cell extracts or nuclear extracts were separated by SDS-PAGE and transferred to PVDF membranes. IRE1a phosphorylation was monitored by Phos-tag SDS-PAGE. PERK phosphorylation was monitored by 5% SDS-PAGE. The following antibodies were used for immunoblot analysis: anti-XBP1s (BioLegend, 619502); anti-PERK (Cell Signaling, 5683); anti-IRE1a (Cell Signaling, 3294); anti-ATF6 (Cosmo bio, BAM-73-500-EX); anti-ATF4 (Santa Cruz, sc-200); anti-Hsp90 (Santa Cruz, sc-7947); anti-TBP (Abcam, 51841); anti-EIF2a (Santa Cruz, sc-11386); anti-phospho-EIF2a (Cell Signaling, 9721). Fig. 1d ). Data are presented relative to b-actin. n 5 5. g, Bioluminescent images of orthotopic tumours formed by luciferaseexpressing MDA-MB-231 cells infected with different lentiviruses. A total of 1.5 3 10 6 cells were injected into the fourth mammary glands of nude mice. Bioluminescent images were obtained 1 week later and serially after mice were begun on chow containing doxycycline (dox) (day 10 Fig. 1f . m, Tumour growth (mean 6 s.e.m.) of BCM-2147 tumours as in Fig. 1f (Scr siRNA, n 5 7; XBP1 siRNA, n 5 2).
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Extended Data Figure 2 | Effect of XBP1 on tumour relapse and CD44 high CD24 low cells. a, Tumour growth of MDA-MB-231 cells untreated or treated with paclitaxel (20 mg kg 21 ), or paclitaxel 1 control shRNA, or paclitaxel 1 XBP1 shRNA in nude mice. TX, treatment with paclitaxel or paclitaxel 1 shRNA. Data are shown as mean 6 s.d. of biological replicates (n 5 5). b, Number of mammospheres per 1,000 cells generated from day 20 xenograft tumours under different treatments as indicated under normoxic or hypoxic condition (0.1% O 2 ). Data are shown as mean 6 s.d. of biological replicates (n 5 3). Asterisk denotes significantly different from paclitaxel 1 shCtrl control in each treatment; *P , 0.05, **P , 0.01. c, Effect of XBP1 knockdown on cell death in hypoxic regions (assessed by CA9 and cleaved caspase 3 staining) or accumulation of CD44 high CD24 low cells (assessed by CD44 staining). Immunohistochemical staining of CA9 and cleaved caspase 3 (consecutive sections) showed that cell death was not induced in hypoxic region in XBP1 knockdown tumours. Immunohistochemical staining of CD44 showed significant reduction of CD44 expression in XBP1 knockdown tumours. All tumour sections are from MDA-MB-231-derived xenograft with different treatment as indicated. diphenyl tetrazolium bromide) assay was performed to measure the dose-response curves of CD44 low CD24 high cells or CD44 low CD24 high cells expressing XBP1s treated with doxorubicin. Experiments were performed in triplicate and data are shown as mean 6 s.d. *P , 0.05, **P , 0.01. d, 1,000 or 100 CD44 low CD24 high cells sorted from transformed MCF10A ER-Src cells or CD44 low CD24 high cells overexpressing XBP1s were injected into NOD/SCID/Il2rc 2/2 mice and the incidence of tumours was monitored. e, Ten CD44 low CD24 high cells sorted from two human patients with TNBC or CD44 low CD24 high cells overexpressing XBP1s were injected into NOD/SCID/Il2rc 2/2 mice and the incidence of tumours was monitored.
